Signal2026-08-11
ClinicalTrials.gov

[PHASE1] Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Part of

Ferroptosis Targeted Lung Cancer Therapies

Open primary sourceRead on Substack